Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Dose Ranging Study of a Drug for the Treatment of Acute Migraine

Study:

Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine

Rationale:

n/a

Purpose:

The purpose of this study is the exploration of a wide range of BMS-927711 doses that will reveal at least one dose that is safe and clinically superior to placebo in the treatment of acute migraine.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Migraine - Acute Drug: Placebo matching BMS-927711
Drug: BMS-927711
Drug: BMS-927711
Drug: BMS-927711
Drug: BMS-927711
Drug: BMS-927711
Drug: BMS-927711
Drug: Sumatriptan
Phase 2

Verified by Bristol-Myers Squibb December, 2012

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov identifier: NCT01430442

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Bristol-Myers Squibb., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site